IIM
PLX icon

INTECH Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

INTECH Investment Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.3K Sell
16,446
-3,512
-18% -$7.44K ﹤0.01% 2079
2026
Q1 		$43.3K Sell
19,958
-11,175
-36% -$27.7K ﹤0.01% 2021
2025
Q4 		$56K Sell
31,133
-115
-0.4% -$235 ﹤0.01% 2251
2025
Q3 		$69.4K Sell
31,248
-5,242
-14% -$8.54K ﹤0.01% 2335
2025
Q2 		$54K Buy
+36,490
New +$74.7K ﹤0.01% 2413

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

INTECH Investment Management's PLX Position: Q2 2026 in Review

INTECH Investment Management reduced its Protalix BioTherapeutics (PLX) stake by 18% in Q2 2026, selling an estimated $7.44K and leaving 16,446 shares worth $38.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2079.

INTECH Investment Management first reported a position in PLX in Q2 2025 and has held it in 5 quarters since. The position peaked at $69.4K in Q3 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • INTECH Investment Management held 16,446 shares of Protalix BioTherapeutics worth $38.3K as of Q2 2026.
  • INTECH Investment Management sold 3,512 Protalix BioTherapeutics shares in Q2 2026, an estimated $7.44K.
  • Protalix BioTherapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #2079 holding.
  • INTECH Investment Management first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 5 quarters since.
  • INTECH Investment Management's Protalix BioTherapeutics position peaked at $69.4K in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.